Brought to you by 
George Mason Univ., PerkinElmer develop cancer biomarker
04 Apr 2006
Executive Summary
George Mason University and PerkinElmer Life & Analytical Sciences have entered into a five-year collaboration to create a new proteomics technology that will precisely detect and measure, from a drop of blood, protein fragments that are indicative of cancer.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
George Mason Univ., PerkinElmer develop cancer biomarker
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice